J Liver Cancer.
2016 Sep;16(2):69-81. 10.17998/jlc.2016.16.2.69.
Locoregional Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
- Affiliations
-
- 1Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea. mongmani@hanmail.net
- 2Department of Hepatobiliary and Pancreatic Surgery, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
- 3Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
- 4Department of Radiology and Radiologic Science, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
- KMID: 2357335
- DOI: http://doi.org/10.17998/jlc.2016.16.2.69
Abstract
- Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) have a extremely poor prognosis. According to the Barcelona Clinic Liver Cancer guideline, sorafenib is a standard therapy in this situation, but many clinicians still select locoregional therapy (LRT) such as transarterial therapy, external beam radiation therapy (EBRT), even surgical resection (SR) or combination of LRTs because the survival improvement by sorafenib is unsatisfactory. Based on recent meta-analysis and prospective study, transarterial chemoembolization (TACE) and transarterial radioembolization seem to be effective and safe therapeutic option that have comparable outcome to sorafenib. Recently large nationwide studies demonstrated that SR can be a potentially curative treatment in selected patients. Hepatic arterial infusion chemotherapy (HAIC) can be also good option, especially in Child class B patients based on small volume prospective studies. Moreover, multidisciplinary strategies based on the combination of LRTs (SR plus TACE, TACE + EBRT, TACE + Sorafenib, HAIC + EBRT etc.) may improve survival of HCC patients with PVTT. Finally we discuss individualized and tailored treatment strategies for different clinical situations.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”
- Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis
- Clinical features of portal vein thrombosis in hepatocellular carcinoma
- Sonographic features of portal vein thrombosis
- 3 Cases of Portal Vein Thrombosis in Hepatocellular Carcinoma and Liver Cirrhosis Treated with Anticoagulation
